Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
Total Valuation
Puma Biotechnology has a market cap or net worth of $246.41M. The enterprise value is $215.01M.
Market Cap$246.41M
Enterprise Value$215.01M
Share Statistics
Puma Biotechnology has 50,391,106 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,391,106
Owned by Insiders16.07%
Owned by Institutions10.83%
Financial Efficiency
Puma Biotechnology’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is 23.14%.
Return on Equity (ROE)0.33
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)23.14%
Return on Capital Employed (ROCE)0.26
Revenue Per Employee1.34M
Profits Per Employee176.03K
Employee Count172
Asset Turnover1.08
Inventory Turnover7.38
Valuation Ratios
The current PE Ratio of Puma Biotechnology is 6.6. Puma Biotechnology’s PEG ratio is 0.14.
PE Ratio6.6
PS Ratio0.64
PB Ratio1.61
Price to Fair Value1.61
Price to FCF3.82
Price to Operating Cash Flow5.80
PEG Ratio0.14
Income Statement
In the last 12 months, Puma Biotechnology had revenue of 230.47M and earned 30.28M in profits. Earnings per share was 0.62.
Revenue230.47M
Gross Profit166.06M
Operating Income30.97M
Pretax Income24.10M
Net Income30.28M
EBITDA48.08M
Earnings Per Share (EPS)0.62
Cash Flow
In the last 12 months, operating cash flow was 42.99M and capital expenditures -123.00K, giving a free cash flow of 42.87M billion.
Operating Cash Flow42.99M
Free Cash Flow42.87M
Free Cash Flow per Share0.85
Dividends & Yields
Puma Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.67
52-Week Price Change61.92%
50-Day Moving Average5.04
200-Day Moving Average3.90
Relative Strength Index (RSI)47.00
Average Volume (3m)586.59K
Important Dates
Puma Biotechnology upcoming earnings date is Feb 26, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Puma Biotechnology as a current ratio of 1.54, with Debt / Equity ratio of 35.61%
Current Ratio1.54
Quick Ratio1.45
Debt to Market Cap0.45
Net Debt to EBITDA0.10
Interest Coverage Ratio2.49
Taxes
In the past 12 months, Puma Biotechnology has paid -6.18M in taxes.
Income Tax-6.18M
Effective Tax Rate-0.26
Enterprise Valuation
Puma Biotechnology EV to EBITDA ratio is 3.19, with an EV/FCF ratio of 3.94.
EV to Sales0.66
EV to EBITDA3.19
EV to Free Cash Flow3.94
EV to Operating Cash Flow3.94
Balance Sheet
Puma Biotechnology has $94.39M in cash and marketable securities with $41.05M in debt, giving a net cash position of $53.34M billion.
Cash & Marketable Securities$94.39M
Total Debt$41.05M
Net Cash$53.34M
Net Cash Per Share$1.06
Tangible Book Value Per Share$0.84
Margins
Gross margin is 76.91%, with operating margin of 13.44%, and net profit margin of 13.14%.
Gross Margin76.91%
Operating Margin13.44%
Pretax Margin10.46%
Net Profit Margin13.14%
EBITDA Margin20.86%
EBIT Margin15.86%
Analyst Forecast
The average price target for Puma Biotechnology is $3.50, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$3.50
Price Target Upside-28.43% Downside
Analyst ConsensusModerate Sell
Analyst Count2
Revenue Growth Forecast-12.96%
EPS Growth Forecast56.02%